{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:55:04Z","timestamp":1793768104446,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01312-x","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:46:16Z","timestamp":1748274376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"1312_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","volume":"29","author":"S Thorsteinsd\u00f3ttir","year":"2023","unstructured":"Thorsteinsd\u00f3ttir S, G\u00edslason GK, Aspelund T, R\u00f6gnvaldsson S, \u00d3skarsson JP, Sigur\u00f0ard\u00f3ttir GA, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023;29:467\u201372.","journal-title":"Nat Med"},{"key":"1312_CR3","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl J Med. 2007;356:2582\u201390.","journal-title":"N. Engl J Med"},{"key":"1312_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102.","journal-title":"Blood Cancer J"},{"key":"1312_CR5","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 2023;10:e203\u2013e212.","journal-title":"Lancet Haematol"},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u2013e312.","journal-title":"Lancet Oncol"},{"key":"1312_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12:129.","journal-title":"Blood Cancer J"},{"key":"1312_CR8","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3324\/haematol.2021.278519","volume":"106","author":"P Musto","year":"2021","unstructured":"Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, de Donk NV, et al. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica. 2021;106:2799\u2013812.","journal-title":"Haematologica"},{"key":"1312_CR9","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. N Engl J Med. 2025;392:1777\u201388.","DOI":"10.1056\/NEJMoa2409029"},{"key":"1312_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020;38:1126\u201337.","journal-title":"J Clin Oncol"},{"key":"1312_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","volume":"174","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Hernandez MT, Salvador C, Rubia J, de Arriba F, L\u00f3pez-Corral L, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. Eur J Cancer. 2022;174:243\u201350.","journal-title":"Eur J Cancer"},{"key":"1312_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Murlow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1312_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1312_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1312_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785\u201394.","journal-title":"Biometrics"},{"key":"1312_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046\u201355.","journal-title":"J Clin Epidemiol"},{"key":"1312_CR17","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","volume":"25","author":"TA Brighton","year":"2019","unstructured":"Brighton TA, Khot A, Harrison SJ, Ghez D, Weiss BM, Kirsch A, et al. Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma. Clin Cancer Res. 2019;25:3772\u20135.","journal-title":"Clin Cancer Res"},{"key":"1312_CR18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez-Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl J Med. 2013;369:438\u201347.","journal-title":"N. Engl J Med"},{"key":"1312_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, orral Lopez-C, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127\u201336.","journal-title":"Lancet Oncol"},{"key":"1312_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/leu.2012.236","volume":"27","author":"TE Witzig","year":"2013","unstructured":"Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2013;27:220\u20135.","journal-title":"Leukemia"},{"key":"1312_CR21","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1312_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.leu.2405016","volume":"22","author":"KC Anderson","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22:231\u20139.","journal-title":"Leukemia"},{"key":"1312_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01109-4","volume":"14","author":"C Pawlyn","year":"2024","unstructured":"Pawlyn C, Schjesvold FH, Cairns DA, Wei LJ, Davies F, Nadeem O, et al. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J. 2024;14:134.","journal-title":"Blood Cancer J"},{"key":"1312_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104529","volume":"204","author":"M Mainou","year":"2024","unstructured":"Mainou M, Tsapa K, Michailidis T, Malandris K, Karagiannis T, Avgerinos I, et al. Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: A systematic review. Crit Rev Oncol Hematol. 2024;204:104529.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1312_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ajh.27582","volume":"100","author":"I Ntanasis-Stathopoulos","year":"2025","unstructured":"Ntanasis-Stathopoulos I, Filippatos C, Ntanasis-Stathopoulos A, Malandrakis P, Kastritis E, Tsitsilonis OE, et al. Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials. Am J Hematol. 2025;100:427\u201338.","journal-title":"Am J Hematol"},{"key":"1312_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144:359\u201367.","journal-title":"Blood"},{"key":"1312_CR27","doi-asserted-by":"crossref","unstructured":"Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Kostopoulos IV, Eleutherakis-Papaiakovou E, Kanellias N, et al. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post ASCT in myeloma. Blood. 2025;145:2353\u201360.","DOI":"10.1182\/blood.2024027686"},{"key":"1312_CR28","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1200\/JCO.23.02771","volume":"42","author":"MV Mateos","year":"2024","unstructured":"Mateos MV, Martinez-Lopez J, Rodriguez Otero P, Gonz\u00e1lez-Calle V, Gonzalez MS, Oriol A, et al. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol. 2024;42:3247\u201356.","journal-title":"J Clin Oncol"},{"key":"1312_CR29","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","volume":"7","author":"D Kazandjian","year":"2021","unstructured":"Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, et al. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2021;7:1678\u201385.","journal-title":"JAMA Oncol"},{"key":"1312_CR30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/10428194.2023.2216818","volume":"64","author":"N Kreiniz","year":"2023","unstructured":"Kreiniz N, Gertz MA. Understanding high-risk smoldering multiple myeloma. Leuk Lymphoma. 2023;64:1361\u201372.","journal-title":"Leuk Lymphoma"},{"key":"1312_CR31","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","volume":"28","author":"R Termini","year":"2022","unstructured":"Termini R, Zihala D, Terpos E, Perez-Monta\u00f1a A, Jel\u00ednek T, Raab M, et al. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma. Clin Cancer Res. 2022;28:4771\u201381.","journal-title":"Clin Cancer Res"},{"key":"1312_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1:493\u2013506.","journal-title":"Nat Cancer"},{"key":"1312_CR33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3324\/haematol.2011.060780","volume":"97","author":"Lopez-Corral","year":"2012","unstructured":"Lopez-Corral, Mateos L, Corchete LA MV, Sarasquete ME, de la Rubia J, de Arriba F, et al. Genomic analysis of high-risk smoldering multiple myeloma. Haematologica. 2012;97:1439\u201343.","journal-title":"Haematologica"},{"key":"1312_CR34","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, et al. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020;38:2380\u20139.","journal-title":"J Clin Oncol"},{"key":"1312_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05058-y","volume":"9","author":"N Bolli","year":"2018","unstructured":"Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9:3363.","journal-title":"Nat Commun"},{"key":"1312_CR36","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24:1867\u201376.","journal-title":"Nat Med"},{"key":"1312_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41375-021-01379-y","volume":"36","author":"EM Boyle","year":"2022","unstructured":"Boyle EM, Rosenthal A, Ghamlouch H, Wang Y, Farmer P, Rutherford M, et al. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2022;36:591\u20135.","journal-title":"Leukemia"},{"key":"1312_CR38","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-24-0210","volume":"30","author":"D Kazandjian","year":"2024","unstructured":"Kazandjian D, Diamond B, Papadimitriou M, Hill E, Sklavenitis-Pistofidis R, Ziccheddu B, et al. Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clin Cancer Res. 2024;30:4482\u201390.","journal-title":"Clin Cancer Res"},{"key":"1312_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.118","volume":"6","author":"C Botta","year":"2016","unstructured":"Botta C, Di Martino MT, Ciliberto D, Cuc\u00e8 M, Correale P, Rossi M, et al. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer J. 2016;6:e511.","journal-title":"Blood Cancer J"},{"key":"1312_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.78","volume":"7","author":"J Hillengass","year":"2017","unstructured":"Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 2017;7:e599.","journal-title":"Blood Cancer J"},{"key":"1312_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/ejh.13749","volume":"108","author":"MT Gundesen","year":"2022","unstructured":"Gundesen MT, Asmussen JT, Haukas E, Schubert M, Abildgaard N, Schjesvold F, et al. A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma. Eur J Haematol. 2022;108:423\u20139.","journal-title":"Eur J Haematol"},{"key":"1312_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00360-9","volume":"10","author":"M Gavriatopoulou","year":"2020","unstructured":"Gavriatopoulou M, Boultadaki A, Koutoulidis V, Ntanasis-Stathopoulos I, Bourgioti C, Malandrakis P, et al. The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer J. 2020;10:93.","journal-title":"Blood Cancer J"},{"key":"1312_CR43","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3390\/jcm14072224","volume":"14","author":"I Ntanasis-Stathopoulos","year":"2025","unstructured":"Ntanasis-Stathopoulos I, Koutoulidis V, Malandrakis P, Fotiou D, Spiliopoulou V, Filippatos C, et al. Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice. J Clin Med. 2025;14:2224.","journal-title":"J Clin Med"},{"key":"1312_CR44","doi-asserted-by":"crossref","unstructured":"Kastritis E, Solia I, Malandrakis P, Theodorakakou F, Ntanasis-Stathopoulos I, Kanellias N et al. Patterns of progression among 427 Smoldering Myeloma patients diagnosed after 2014: importance of monitoring. Blood Adv. 2025: bloodadvances.2025016083. Online ahead of print.","DOI":"10.1182\/bloodadvances.2025016083"},{"key":"1312_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00980-5","volume":"14","author":"NH Abdallah","year":"2024","unstructured":"Abdallah NH, Lakshman A, Kumar SK, Cook J, Binder M, Kapoor P, et al. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 2024;14:9.","journal-title":"Blood Cancer J"},{"key":"1312_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.","journal-title":"Blood Cancer J"},{"key":"1312_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01159-8","volume":"14","author":"A Werly","year":"2024","unstructured":"Werly A, Hampel M, Hielscher T, Zuern K, Schmidt SK, Visram A, et al. Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma. Blood Cancer J. 2024;14:176.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01312-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:02:19Z","timestamp":1748278939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01312-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01312-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"INS declares honoraria from Janssen. PM declares honoraria from Janssen. EK declares honoraria from Amgen, Janssen, GSK, and Pfizer. ET declares honoraria from Amgen, Astra\/Zeneca, Bristol Myers Squibb, Eusa Pharma, GSK, Integris Pharma, Janssen, Pfizer, Sanofi, and Takeda. MAD declares honoraria from Abbvie, Amgen, Bristol Myers Squibb, GSK, Janssen, Karyopharm, Pharmacyclics Inc, Pfizer, Sanofi, and Takeda. MG declares honoraria from GSK, Janssen, Sanofi, Abbvie, Amgen, and Takeda. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"An ethics approval was not required for this study as it is a systematic review and meta-analysis that synthesizes previously published, peer-reviewed data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not required for this study as it is a systematic review and meta-analysis that synthesizes previously published, peer-reviewed data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"104"}}